You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Our Medicines

Learn More | Tivicay + Lamivudine

TIVICAY (dolutegravir) + Lamivudine

View Details

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.1

Epivir is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults and children.2

 Tivicay Summary of Product Characteristics

 Epivir Summary of Product Characteristics

Learn More | Juluca

JULUCA ▼(dolutegravir/rilpivirine)

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable ARV regimen for ≥6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.3

Juluca Summary of Product Characteristics

Download: Juluca Patient Information Guide

Order: Juluca Patient Information Guide

TRIUMEQ (dolutegravir/abacavir/lamivudine)

Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.4

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patient known to carry the HLA-B*5701
allele.
4

Triumeq Summary of Product Characteristics

Download: Triumeq Patient Information Guide

Order: Triumeq Patient Information Guide

Learn More | Tivicay

TIVICAY (dolutegravir)

Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.1

Tivicay Summary of Product Characteristics

Tivicay + lamivudine is only suitable for the treatment of HIV-1 infection where there is no known or suspected resistance to the integrase inhibitor class, or to lamivudine.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the ViiV Healthcare group of companies.